In the present study, we demonstrated that CCL17 deficiency and the therapeutic administration of CCL17 neutralizing antibodies attenuated Ang II–induced and age-related cardiac hypertrophy, fibrosis, and subsequent HF. The gene discussed is CCL17; the disease is hydrops fetalis.